These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 15756017)

  • 1. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
    Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T
    Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Ishikawa A; Ishikawa E; Otsuji M; Iizasa T; Hanaoka H; Shimizu N; Horiguchi S; Okamoto Y; Fujii S; Taniguchi M; Fujisawa T; Nakayama T
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6079-86. PubMed ID: 17028247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
    J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
    Giaccone G; Punt CJ; Ando Y; Ruijter R; Nishi N; Peters M; von Blomberg BM; Scheper RJ; van der Vliet HJ; van den Eertwegh AJ; Roelvink M; Beijnen J; Zwierzina H; Pinedo HM
    Clin Cancer Res; 2002 Dec; 8(12):3702-9. PubMed ID: 12473579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Translational research in patients with lung cancer--clinical application of NKT cell immunotherapy].
    Motohashi S
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):550-3. PubMed ID: 17431340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide.
    Toura I; Kawano T; Akutsu Y; Nakayama T; Ochiai T; Taniguchi M
    J Immunol; 1999 Sep; 163(5):2387-91. PubMed ID: 10452972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of clinical and immunological effects of intravenous and intradermal administration of α-galactosylceramide (KRN7000)-pulsed dendritic cells.
    Nicol AJ; Tazbirkova A; Nieda M
    Clin Cancer Res; 2011 Aug; 17(15):5140-51. PubMed ID: 21653690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
    Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
    Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients.
    Motohashi S; Kobayashi S; Ito T; Magara KK; Mikuni O; Kamada N; Iizasa T; Nakayama T; Fujisawa T; Taniguchi M
    Int J Cancer; 2002 Nov; 102(2):159-65. PubMed ID: 12385012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
    van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ
    Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.
    Osada T; Morse MA; Lyerly HK; Clay TM
    Int Immunol; 2005 Sep; 17(9):1143-55. PubMed ID: 16027139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
    Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
    Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
    Fujii S; Shimizu K; Hemmi H; Steinman RM
    Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy.
    Yamasaki K; Horiguchi S; Kurosaki M; Kunii N; Nagato K; Hanaoka H; Shimizu N; Ueno N; Yamamoto S; Taniguchi M; Motohashi S; Nakayama T; Okamoto Y
    Clin Immunol; 2011 Mar; 138(3):255-65. PubMed ID: 21185787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
    Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
    Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide].
    Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion of Valpha24(+)Vbeta11(+) NKT cells from cord blood mononuclear cells using IL-15, IL-7 and Flt3-L depends on monocytes.
    Okada H; Nagamura-Inoue T; Mori Y; Takahashi TA
    Eur J Immunol; 2006 Jan; 36(1):236-44. PubMed ID: 16380959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells.
    Imataki O; Heike Y; Makiyama H; Iizuka A; Ikarashi Y; Ishida T; Wakasugi H; Takaue Y
    Cytotherapy; 2008; 10(5):497-506. PubMed ID: 18608348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma.
    Kunii N; Horiguchi S; Motohashi S; Yamamoto H; Ueno N; Yamamoto S; Sakurai D; Taniguchi M; Nakayama T; Okamoto Y
    Cancer Sci; 2009 Jun; 100(6):1092-8. PubMed ID: 19302288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
    Morse MA; Clay TM; Hobeika AC; Osada T; Khan S; Chui S; Niedzwiecki D; Panicali D; Schlom J; Lyerly HK
    Clin Cancer Res; 2005 Apr; 11(8):3017-24. PubMed ID: 15837756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.